MND Victoria Logodonatenow

Twitter pageFacebook pageInstagram

Edaravone approved to treat MND by US FDA

Edaravone chemical structureOn 5 May 2017, the US Food and Drugs Administration (FDA) approved the drug edaravone (which will be marketed as Radicava™) for the treatment of amyotrophic lateral sclerosis (ALS) or motor neurone disease (MND) in the United States (US). It is the first drug to approved for MND/ALS in 22 years.

Download MND Australia's Edaravone fact sheet.

On Tuesday, 9th May 2017 at our Ask the Experts MND research seminar and lab tours at the Florey Institute of Neuroscience and Mental Health, our CEO Rod Harris interviewed Dr Bradley Tuner about the announcement:

Dr Brad Turner, edaravone molecule on computer screen in background

Follow MND Victoria on Facebook and Twitter and Subscribe to our Newsletter to stay up-to-date with the latest news on Edaravone.

MND Victoria
Back to Top